Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park and Myung-Ju Ahn Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors Cancer 117
Article first published online: 27 AUG 2010 | DOI: 10.1002/cncr.25560
Patients with wild-type epidermal growth factor receptor (WT EGFR)-positive nonsmall cell lung cancer (NSCLC) may benefit clinically from treatment with EGFR tyrosine kinase inhibitors (TKIs) through the regulation of amphiregulin expression. The results suggested that amphiregulin expression may be another potential marker for the selection of EGFR-TKI treatment in patients with WT EGFR-positive NSCLC.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.